Pruebas diagnósticas

Predictive ability of direct-to-consumer pharmacogenetic testing

Incorporating direct-to-consumer genomic information into patient care

The limits of genome-wide methods for pharmacogenomic testing

Saliva samples-viable alternative to blood samples as a source of DNA for genotyping

Generic-genetic transition in cardiovascular and neuropsychiatric drugs

Current state and future prospects of direct-to-consumer pharmacogenetics

Creating and evaluating genetic tests predictive of drug response

Challenges in pharmacogenomics testing

Systematic review of pharmacoeconomic studies of pharmacogenomics tests

Regresar al Acervo